Patents Assigned to SIXERA PHARMA AB
  • Benzoxazinone derivatives for treatment of skin diseases
    Patent number: 10072024
    Abstract: The present invention relates to methods and compositions for inhibiting the activity of skin proteases, especially human kallikrein 7 (KLK7), human kallikrein 5 (KLK5), and human kallikrein 14 (KLK14). More specifically, the invention relates to the use of substituted 3,1-benzoxazin-4-ones being selective inhibitors of human skin kallikreins for the treatment of skin diseases, more specifically for the treatment of inflammatory skins diseases, especially Netherton syndrome.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: September 11, 2018
    Assignee: SIXERA PHARMA AB
    Inventors: Fredrik Wagberg, Goran Leonardsson
  • Kallikrein 7 inhibitors
    Patent number: 9744148
    Abstract: The present invention relates to methods for inhibiting the activity of human kallikrein 7 (KLK7) (also known as serine protease stratum corneum chymotryptic enzyme, SCCE). The invention further relates to the use of KLK7 inhibitors of Formula I for the treatment and prevention of diseases, more specifically for the treatment and prevention of skin diseases. The invention also provides new compounds demonstrated to be inhibitors of KLK7.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: August 29, 2017
    Assignee: SIXERA Pharma AB
    Inventor: Marcel Linschoten
  • Benzoxazinone derivatives for treatment of skin diseases
    Patent number: 9695194
    Abstract: The present invention relates to methods and compositions for inhibiting the activity of skin proteases, especially human kallikrein 7 (KLK7), human kallikrein 5 (KLK5), and human kallikrein 14 (KLK14). More specifically, the invention relates to the use of substituted 3,1-benzoxazin-4-ones being selective inhibitors of human skin kallikreins for the treatment of skin diseases, more specifically for the treatment of inflammatory skins diseases, especially Netherton syndrome.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: July 4, 2017
    Assignee: SIXERA PHARMA AB
    Inventors: Fredrik Wagberg, Goran Leonardsson